Contineum Q2 cash $218.7M; PIPE-307 Phase 2 enrollment on track

Contineum Therapeutics, Inc.

2024-Q2 EPS reported -$1.35

Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at year-end 2023.
R&D expenses $7.9M vs $9.5M YoY; G&A expenses $3.0M vs $1.6M YoY.
Completed IPO in April 2024, net proceeds $107.9M.
Phase 2 VISTA trial of PIPE-307 for RRMS enrollment on track, completion expected in 2025.
Strengthened board and management with four new appointments, including Troy Ignelzi and Sarah Boyce.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.